Drug Resistant Epilepsy: Clinical Trials

18 trials for Drug Resistant Epilepsy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated, 5 completed, 3 recruiting, 2 active not recruiting. 18 Phase 3, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 318Terminated 6, Completed 5, Recruiting 3, Active not recruiting 2, Unknown 1, Withdrawn 1
Phase 210Completed 3, Terminated 3, Active not recruiting 2, Recruiting 1, Withdrawn 1

Follow Drug Resistant Epilepsy: new trials by email Literature Review of Drug Resistant Epilepsy trials Research Report on Drug Resistant Epilepsy

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials
Cannabidiol (CBD) oral solution, Placebo - Refractory Epilepsy in Children, Refractory Epilepsy
Phase 3RecruitingUMC Utrecht502025-02-062026-06-25
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
BHV-7000, Placebo - Generalized Epilepsy
Phase 2 / Phase 3TerminatedBiohaven Therapeutics Ltd.272024-06-202026-03-24
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
BHV-7000, Placebo - Focal Epilepsy
Phase 2 / Phase 3Active not recruitingBiohaven Therapeutics Ltd.3902024-05-132026-08-13
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
BHV-7000, Placebo - Focal Epilepsy
Phase 2 / Phase 3Active not recruitingBiohaven Therapeutics Ltd.3902024-03-142026-09-30
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
Rapamycin, Placebo - Tuberous Sclerosis Complex
Phase 3RecruitingKatarzyna Kotulska2002023-01-232026-10-22
Exogenous Ketone Esters for Drug Resistant Epilepsy
Exogenous ketone ester - Drug Resistant Epilepsy
Phase 2 / Phase 3RecruitingSohag University602023-01-102024-11-27
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Vatiquinone - Inherited Mitochondrial Disease
Phase 3CompletedPTC Therapeutics1012022-06-222025-12-22
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy
Phase 2 / Phase 3TerminatedPTC Therapeutics682020-09-282026-03-31
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
Padsevonil, Placebo - Drug-Resistant Epilepsy, Focal-Onset Seizures
Phase 3TerminatedUCB Biopharma SRL2322019-03-062022-12-21
Cannabis Extract in Refractory Epilepsy Study
Medical Cannabis, Placebo - Drug Resistant Epilepsy
Phase 3TerminatedThe Epilepsy Research Program of the Ontario Brain Institute172019-01-102020-09-11
Vitamine D in Drug Resistant Epilepsy
Cholecalciferol, Placebo Oral - Drug Resistant Epilepsy
Phase 3CompletedCentre Hospitalier St Anne882018-04-032024-07-12
Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus
Traditional Treatment (Group T), Ketamine Infusion (Group K) - Refractory Epilepsy
Phase 2 / Phase 3WithdrawnUniversity of Alabama at Birmingham2017-05-042021-05-21
Comparison of the Effectiveness of the Outpatient Classical Ketogenic Diet and Modified Atkins Diet on Seizures Frequency, Nutritional Status and Some Biochemical Factors in Children and Adolescents With Intractable Epilepsy
Classical ketogenic diet, Modified Atkins diet - Epilepsy Intractable
Phase 2 / Phase 3CompletedTehran University of Medical Sciences502016-09-012017-09-07
Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy
Modified Atkin Diet - Refractory Epilepsy
Phase 2 / Phase 3CompletedLady Hardinge Medical College312012-11-012019-01-15
Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy
Simplified Modified Atkins Diet, Antiepileptic drugs alone - Refractory Epilepsy
Phase 2 / Phase 3CompletedLady Hardinge Medical College812012-09-012019-01-15
Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy
Low glycemic index diet, Control group - Refractory Epilepsy
Phase 3UnknownAll India Institute of Medical Sciences402011-06-012012-07-20
Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)
levetiracetam - Epilepsy, Drug Resistant
Phase 3TerminatedUniversity Hospital, Grenoble1122007-02-012015-05-28
STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy
Neurostimulation - Epilepsy, Drug Resistant
Phase 2 / Phase 3TerminatedUniversity Hospital, Grenoble42005-09-012015-05-28

Narrower conditions

Epilepsy (10)  ·  Seizures (7)  ·  Diffuse Cerebral Sclerosis of Schilder (2)  ·  Epilepsies, Partial (2)  ·  Leigh Disease (2)  ·  MELAS Syndrome (2)  ·  MERRF Syndrome (2)  ·  Color Vision Defects (1)  ·  Epilepsy, Absence (1)  ·  Epilepsy, Generalized (1)  ·  Epilepsy, Idiopathic Generalized (1)  ·  Marijuana Abuse (1)  ·  Mitochondrial Diseases (1)  ·  Mitochondrial Encephalomyopathies (1)

Broader conditions

Brain Diseases (18)  ·  Central Nervous System Diseases (18)  ·  Nervous System Diseases (18)  ·  Epilepsy (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Neurologic Manifestations (7)  ·  Signs and Symptoms (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Epilepsies, Myoclonic (3)  ·  Epileptic Syndromes (3)  ·  Genetic Diseases, Inborn (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Autoimmune Diseases (2)  ·  Autoimmune Diseases of the Nervous System (2)  ·  Brain Diseases, Metabolic (2)

Interventions

alpha-tocotrienol quinone (2)  ·  Anticonvulsants (1)  ·  Barbiturates (1)  ·  Benzodiazepines (1)  ·  Cannabidiol (1)  ·  Cholecalciferol (1)  ·  Control Groups (1)  ·  Ketamine (1)  ·  Levetiracetam (1)  ·  Medical Marijuana (1)  ·  Propofol (1)  ·  Sensitivity Training Groups (1)  ·  Sirolimus (1)  ·  mycophenolic adenine dinucleotide (1)  ·  padsevonil (1)

Sponsors

Biohaven Therapeutics Ltd. (3)  ·  Lady Hardinge Medical College (2)  ·  PTC Therapeutics (2)  ·  University Hospital, Grenoble (2)  ·  All India Institute of Medical Sciences (1)  ·  Centre Hospitalier St Anne (1)  ·  Katarzyna Kotulska (1)  ·  Sohag University (1)  ·  Tehran University of Medical Sciences (1)  ·  The Epilepsy Research Program of the Ontario Brain Institute (1)  ·  UCB Biopharma SRL (1)  ·  UMC Utrecht (1)  ·  University of Alabama at Birmingham (1)

Countries

France (8)  ·  Poland (7)  ·  United States (7)  ·  Italy (5)  ·  Spain (5)  ·  United Kingdom (5)  ·  India (4)  ·  Australia (3)  ·  Belgium (3)  ·  Finland (3)  ·  Germany (3)  ·  Hungary (3)  ·  Japan (3)  ·  Netherlands (3)  ·  Portugal (3)

Top investigators

Satinder Aneja, MD (2)  ·  Vinay Penematsa, MD (2)  ·  Abdelrahim A Sadek, MD, PhD (1)  ·  Danielle Andrade, MD (1)  ·  Louis Maillard, Dr (1)  ·  Nancy Mingo, MD (1)  ·  Peter Tai, MD (1)

Results publications

PMID 30232735, PMID 32588435, PMID 36176044, PMID 38980968

NIH funding

2023 (4), 2018 (1)